Healthcare

CVS Group Reports 6.6% Increase in Sales for H1 2025 Amid Market Cha...

Highlights,Sales Growth:,Group sales up 6.6%, totaling £341.8m for H1 2025.,Adjusted EBITDA:,Increased by 4.5% to £67.4m, with an EBITDA margin of 19....

hVIVO Acquires Two Clinical Research Units in €10M Deal to Expand Eu...

Highlights,hVIVO acquires two German clinical research units,from CRS for,€10 million,in cash.,Expands services to include Phase I and II trials,acros...

ImmuPharma (LON:IMM) Trading Up 9.3%: Positive Movement in Specialty...

Highlights,ImmuPharma's (IMM) share price surged by 9.3% on Saturday.,The company saw significant trading volume with a 60% increase from average dail...

Hikma Pharmaceuticals (LON:HIK) Hits New 52-Week High Amid Positive...

Highlights,Hikma Pharmaceuticals reaches a new 52-week high, signaling strong market performance.,Stock shows impressive growth with a significant inc...

hVIVO Secures £2.7m Laboratory Services Contract, Marking Largest St...

Highlight,Major Contract Win:,hLAB signs a £2.7m contract for a Phase 2 influenza drug trial, bringing the project's total value to £3.2m.,Internation...

Creo Medical Group PLC (LON:CREO) Insider Purchase Reflects Confiden...

Highlights,Christopher Paul Hancock acquired 4,712 shares of Creo Medical Group (CREO).,The stock opened lower on Tuesday, reflecting a slight market...

ImmuPharma (LON:IMM) Sees 27.6% Surge – What’s Driving the Momentum?

Highlights,ImmuPharma's (IMM) shares surged by 27.6% during recent trading.,Stock reached a high of GBX 3.60 before closing at GBX 3.35.,Market capita...

ImmuPharma (LON:IMM) Climbs 27.6% Amid Renewed Focus on Therapeutic...

Highlights,ImmuPharma shares surged 27.6% during recent trading, reaching an intraday high of GBX 3.60.,Trading volume saw a 61% decline from the aver...

ImmuPharma (LON:IMM) Experiences Notable Stock Surge of 27.6%

Highlights,ImmuPharma (IMM) shares surged by 27.6% during Saturday's trading session.,Stock peaked at GBX 3.60, closing at GBX 3.35, marking a signifi...

ImmuPharma (LON:IMM) Rises 27.6% Amid Renewed Market Interest

Highlights,ImmuPharma shares climbed 27.6% during recent trading, reaching GBX 3.60 at their peak.,Trading volume declined 61% compared to the average...

ImmuPharma (LON:IMM) Sees 27.6% Rise in Stock Price

Highlights,ImmuPharma (IMM) stock price surged 27.6% on Saturday.,Trading volume reached 8,992,934 shares, marking a 61% decrease from the average.,Th...

Futura Medical's Stock Movement and Healthcare Innovations

Headlines,Futura Medical's Momentum Shifts Below Moving Average,Exploring Futura's Pharmaceutical Innovations,Understanding Futura's Strategic Product...

Avacta Therapeutics Announces Promising Tumor Shrinkage Data in Sali...

Highlights,Encouraging Results in Salivary Gland Cancer:,New Phase 1a data shows meaningful tumor shrinkage in patients with salivary gland cancer (SG...

Genus Expects FY25 Half-Year Performance to Exceed Expectations

Highlights:,Adjusted Profit Before Tax Expected to Exceed £35 Million,Strong Performance Across ABS and PIC Divisions,Progress in PRRS1 Resistant Pig...

Biotech Growth Trust: Insights into Recent Insider Activity and Stra...

Headlines,Nicola Shepherd, an insider at The Biotech Growth Trust PLC, made a notable share purchase.,The Biotech Growth Trust PLC focuses on investme...

Gym Group Faces Key Market Challenges Amid Insider Confidence

Headlines,The Gym Group's stock crosses below key moving averages.,Insider activity shows confidence in the company's performance.,Key financial metri...

Trellus Health Partners with Johnson & Johnson for Inflammatory Bowe...

Highlights:,Strategic Partnership,: Trellus Health will integrate its Trellus Elevate™ program into a Patient Support Program (PSP) for eligible patie...

Oxford Nanopore Technologies Sees Strong Growth Amidst Innovation in...

Headlines,Oxford Nanopore Gains Momentum in Trading,Innovative Technologies Elevate Oxford Nanopore,Strategic Advancements Spark Renewed Interest,Oxfo...

ImmuPharma Gains Momentum with Promising Lupuzor Developments

Headlines,ImmuPharma's Performance Gains Momentum,Focus on Innovative Therapeutics,Lupuzor: A Promising Development,ImmuPharma plc (LON:IMM),recently...

GSK to Acquire IDRx for $1.15 Billion, Strengthening Precision Thera...

Highlights,Strategic Acquisition,: GSK will pay $1 billion upfront, with an additional $150 million tied to regulatory approval milestones.,Breakthrou...